HC Wainwright Has Pessimistic View of UBX FY2026 Earnings

Unity Biotechnology, Inc. (NASDAQ:UBX) – Equities researchers at HC Wainwright lowered their FY2026 earnings per share estimates for shares of Unity Biotechnology in a research report issued on Monday, March 24th. HC Wainwright analyst M. Caufield now expects that the company will post earnings per share of ($0.65) for the year, down from their previous estimate of ($0.42). HC Wainwright currently has a “Buy” rating and a $4.00 target price on the stock. The consensus estimate for Unity Biotechnology’s current full-year earnings is ($1.45) per share. HC Wainwright also issued estimates for Unity Biotechnology’s FY2027 earnings at ($0.09) EPS, FY2028 earnings at $0.25 EPS and FY2029 earnings at $0.40 EPS.

Separately, Chardan Capital reduced their price target on shares of Unity Biotechnology from $6.00 to $4.00 and set a “buy” rating on the stock in a research report on Tuesday.

Unity Biotechnology Price Performance

Shares of UBX opened at $1.20 on Thursday. The stock has a market capitalization of $20.24 million, a PE ratio of -0.92 and a beta of 1.02. The business’s fifty day moving average price is $1.89 and its 200 day moving average price is $1.51. Unity Biotechnology has a 12-month low of $0.94 and a 12-month high of $3.10.

Institutional Trading of Unity Biotechnology

A hedge fund recently raised its stake in Unity Biotechnology stock. Bridgeway Capital Management LLC boosted its stake in Unity Biotechnology, Inc. (NASDAQ:UBX) by 100.0% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 50,000 shares of the company’s stock after buying an additional 25,000 shares during the period. Bridgeway Capital Management LLC owned 0.30% of Unity Biotechnology worth $49,000 as of its most recent SEC filing. Institutional investors and hedge funds own 29.49% of the company’s stock.

About Unity Biotechnology

Unity Biotechnology, Inc, a biotechnology company, engages in the research and development of therapeutics to slow, halt, or reverse diseases of aging. The company's lead drug candidate includes UBX1325, which is Phase 2 clinical trial for the treatment of age-related diseases of the eye, including diabetic macular edema, age-related macular degeneration, and diabetic retinopathy.